SRS
8
4
5
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
13%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (8)
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Measuring and Mapping Cognitive Decline After Brain Radiosurgery
Impact of Curve Magnitude on Pain and Body Image in Patients With Adolescents Idiopathic Scoliosis
Combined Gamma Knife/Linac Radiosurgery for Large Brain Tumors / Metastases
SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
Efficacy of the RayerKnife X Stereotactic Radiotherapy System in the Treatment of Brain Metastases
Quality of Life (HRQoL) of AIS Patients Who Require Bracing or Surgery Using SRS-22 Questionnaire
SRS Sequential Sindilimab in Brain Metastasis of NSLSC